Scientific ReportsMolecular BiologyPeer-reviewed journal article
Tryptophan-like side chain holding aptamers inhibit respiratory syncytial virus infection of lung epithelial cells
Krisztina PerczeiD, Zoltán János Tolnai, Marc J. EleveldiD, Li OuiD, Haijuan Du, Adam S. OliaiD, Peter D. KwongiD, Marien Isaäk de JongeiD, Tamás MészárosiD
Abstract
Respiratory syncytial virus (RSV) is a leading cause of serious and even fatal acute lower respiratory tract infections in infants and in the elderly. Potent RSV neutralization has been achieved by antibodies that selectively bind the prefusion form of the viral fusion (F) protein. We hypothesised that similar potent neutralization could be achieved using F protein targeting aptamers. Aptamers have yet to reach their translational potential for therapeutics or diagnostics due to their short half-life and limited range of target-aptamer interactions; these shortcomings can, however, be ameliorated by application of amino acid-like side chain holding nucleotides. In this study, a stabilized version of the prefusion RSV F protein was targeted by aptamer selection using an oligonucleotide library holding a tryptophan-like side chain. This process resulted in aptamers that bound the F protein with high affinity and differentiated between pre- and postfusion conformation. Identified aptamers inhibited viral infection of lung epithelial cells. Moreover, introduction of modified nucleotides extended aptamer half-lives. Our results suggest that targeting aptamers to the surface of viruses could yield effective drug candidates, which could keep up with the pace of the continuously evolving pathogens.
- Citations
- 5
- FWCI
- 0.44
- Field percentile
- top 48%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Flexible RSV prefusogenic fusion glycoprotein exposes multiple neutralizing epitopes that may collectively contribute to protective immunity
N. Natel, J.-H. Tian, … G. Smith·bioRxiv·Sep 14, 2020
- RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera
Cassandra A. L. Simonich, Teagan E. McMahon, … Jesse D. Bloom·Journal of VirologyPeer-reviewed·Jul 3, 2025
- Identification of ICAM-1-targeting DNA aptamers as a host-directed strategy to inhibit Human Rhinovirus infection
Jessica Dellavedova, Chiara Campera, … Paolo Ciana·bioRxiv·Apr 21, 2026
- The Respiratory Syncytial Virus G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-like Particle Vaccine Candidate
L. W. McGinnes-Cullen, B. Luo, … T. G. Morrison·bioRxiv·Sep 12, 2022
- Antiviral activity of the non-steroidal anti-inflammatory drug indomethacin against Respiratory Syncytial Virus
Caterina Tramontozzi, Anna Riccio, … Maria Gabriella Santoro·Virus ResearchPeer-reviewed·May 7, 2026
- A hierarchical activation threshold shapes RSV F antibody repertoires from toddler vulnerability to adult protection
Jie Deng, Yixin Li, … Xiangxi Wang·bioRxiv·Jul 29, 2026